A Human Glucagon-Like Peptide-1-albumin Recombinant Protein with Prolonged Hypoglycemic Effect Provides Efficient and Beneficial Control of Glucose Metabolism in Diabetic Mice-Reference-Cited by-同舟云学术

A Human Glucagon-Like Peptide-1-albumin Recombinant Protein with Prolonged Hypoglycemic Effect Provides Efficient and Beneficial Control of Glucose Metabolism in Diabetic Mice

Published:2017 Issue:9 Volume:40 Page:1399-1408
ISSN:0918-6158
Container-title:Biological & Pharmaceutical Bulletin
language:en
Short-container-title:Biol. Pharm. Bull.

Author:

Li Caina¹,Yang Miaomiao¹,Hou Guojiang¹,Liu Shuainan¹,Huan Yi¹,Yu Dongan²,Sun Sujuan¹,Liu Quan¹,Yan Shousheng²,Shen Zhufang¹

Affiliation:

1. State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College

2. Jiangsu T-mab Biopharma Co., Ltd.

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

https://www.jstage.jst.go.jp/article/bpb/40/9/40_b17-00169/_pdf

Reference23 articles.

1. 1) Neumiller JJ. Incretin-based therapies. Med. Clin. North Am., 99, 107–129 (2015).

2. 2) Taguchi K, Chuang VT, Maruyama T, Otagiri M. Pharmaceutical aspects of the recombinant human serum albumin dimer: structural characteristics, biological properties, and medical applications. J. Pharm. Sci., 101, 3033–3046 (2012).

3. 3) Flisiak R, Flisiak I. Albinterferon-alpha 2b: a new treatment option for hepatitis C. Expert Opin. Biol. Ther., 10, 1509–1515 (2010).

4. 4) Baggio LL, Huang Q, Brown TJ, Drucker DJ. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes, 53, 2492–2500 (2004).

5. 5) Tiessen RG, Castaigne JP, Dreyfus JF, Nemansky M, Kruizinga HH, van Vliet AA. Pharmacokinetics and tolerability of a novel long-acting glucagon-like peptide-1 analog, CJC-1131, in healthy and diabetic subjects. Int. J. Clin. Pharmacol. Ther., 46, 443–452 (2008).

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gentiopicroside modulates glucose homeostasis in high-fat-diet and streptozotocin-induced type 2 diabetic mice;Frontiers in Pharmacology;2023-08-04

2. Stachyose Improves the Effects of Berberine on Glucose Metabolism by Regulating Intestinal Microbiota and Short-Chain Fatty Acids in Spontaneous Type 2 Diabetic KKAy Mice;Frontiers in Pharmacology;2020-10-22

3. Effects of a ready‐to‐eat cereal formula powder on glucose metabolism, inflammation, and gut microbiota in diabetic db/db mice;Food Science & Nutrition;2020-06-29

4. Novel fatty chain-modified GLP-1R G-protein biased agonist exerts prolonged anti-diabetic effects through targeting receptor binding sites;RSC Advances;2020

5. Berberine combined with stachyose induces better glycometabolism than berberine alone through modulating gut microbiota and fecal metabolomics in diabetic mice;Phytotherapy Research;2019-12-13